On Tuesday, Shares of Noble Energy, Inc. (NYSE:NBL), gained 2.18% to $31.40.
Noble Energy, offered new third quarter 2015 sales volume guidance, with the midpoint of the Company’s new expectation representing a 10 thousand barrel of oil equivalent per day (MBoe/d) improvement over the midpoint of its preceding estimate. Following strong volume performance in July and August, the Company has raised its anticipated third quarter 2015 sales volume range to between 360 and 370 MBoe/d. The improvement was driven primarily by improved well performance and infrastructure expansion in the DJ Basin. In addition, strong production is resulting from the Company’s assets in Texas (Eagle Ford and Delaware), Marcellus Shale, Israel, and Equatorial Guinea. Natural gas sales in Israel set a record in August as the Company’s Tamar asset averaged more than one billion cubic feet of natural gas per day, gross, for the month.
Gary W. Willingham, the Company’s Executive Vice President of Operations, commented, “The expansion of natural gas processing systems in Greater Wattenberg has continued to unlock the productive capacity of our DJ Basin operations. Production from our legacy vertical wells and older horizontal wells are benefitting from substantially reduced line pressures and improved third-party plant uptime. We have also continued to materially grow production from the East Pony Integrated Development Plan, which is primarily crude oil and is entirely handled by Noble Energy owned midstream assets. Strong production performance in our business is resulting from execution momentum and the benefits of operating a high-quality and diversified portfolio, despite reducing capital investment materially quarter over quarter throughout the year.”
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in onshore DJ Basin and Marcellus Shale, the United States; the deepwater Gulf of Mexico; offshore West Africa; and offshore Eastern Mediterranean.
Shares of CVS Health Corp (NYSE:CVS), inclined 2.02% to $102.14, during its last trading session.
CVS Health, Research Institute study published in JAMA Internal Medicine is the first to evaluate the impact of narrow pharmacy networks on medication adherence. The analysis showed that this approach, which incentivizes plan members to use specific in-network pharmacies, is associated with improved medication adherence. In addition, the researchers observed an even greater impact on adherence when there were 90-day prescription programs also in place. Narrow networks have formerly been criticized for limiting access and adversely influencing medication adherence.
“There are few opportunities in health care when we can improve both quality of care and health outcomes while assisting to manage health care costs,” said William H. Shrank, MD, MSHS, senior vice president and Chief Scientific Officer, CVS Health and a study author. “This first-of-its-kind study suggests that narrow networks may be one such opportunity by providing clear evidence that these networks – already an established cost administration strategy – also assist optimize members’ adherence.”
The researchers reviewed de-identified pharmacy claims data for more than 200,000 patients on chronic therapies to treat high cholesterol, high blood pressure, diabetes, and depression over a 12-month period. These patients received prescription drug coverage through CVS/caremark, the pharmacy benefit administration (PBM) business of CVS Health. The study found that those patients in commercial drug plans with narrow pharmacy networks had improved medication adherence as indicated by their medication possession ratio (MPR), which measures patients’ available medication on hand over time and is commonly used as an indication of adherence. The researchers also found that if 90-day prescription programs, where patients receive a three-month supply of their chronic medication prescription during one pharmacy visit, were used in conjunction with a narrow network there was an even greater improvement in members’ adherence.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments.
Finally, Gap Inc (NYSE:GPS), ended its last trade with 1.05% gain, and closed at $32.75.
Gap Inc., stated second quarter fiscal year 2015 results and reaffirmed its full-year earnings per share guidance to be in the range of $2.75 to $2.80, not taking into account the impact from planned actions formerly declared on June 15, 2015.
“I remain confident in our strategies to improve business performance and drive loyalty going forward,” said Art Peck, chief executive officer, Gap Inc. “Our evolving product operating model is laying the foundation to more consistently deliver on-trend product collections across our portfolio.”
On a stated basis, Gap Inc.’s second quarter of fiscal year 2015 diluted earnings per share were $0.52, counting the negative impacts associated with foreign currency fluctuations, West Coast port delays, and the planned actions.
Not Taking into Account the negative impact of about $0.12 from the planned actions, the company’s adjusted diluted earnings per share were $0.64 for the second quarter of fiscal year 2015. Please see the reconciliation of adjusted diluted earnings per share, a non-GAAP financial measure, from the GAAP financial measure in the table at the end of this press release.
The Gap, Inc. operates as an apparel retail company worldwide. It offers apparel, accessories, and personal care products for men, women, and children under the Gap, Banana Republic, Old Navy, Athleta, and Intermix brand names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
